Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, Rebecca Asher, Manuel Rodrigues, Jonathan A Ledermann, Ursula A Matulonis, Amit M Oza, Ilan Bruchim, Tomasz Huzarski, Charlie Gourley, Philipp Harter, Ignace Vergote, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tsveta Milenkova, Eric Pujade-Lauraine, Val Gebski, Chee K Lee
EUROPEAN JOURNAL OF CANCER | ELSEVIER SCI LTD | Published : 2021
BACKGROUND: The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer (PSROC) varies widely. Individual prognostic factors do not reliably distinguish patients who progress early from those who have durable benefit. We developed and validated a prognostic nomogram to predict PFS in these patients. METHODS: The nomogram was developed using data from a training patient cohort with BRCA mutations and high-grade serous PSROC on the placebo arm of two maintenance therapy trials, Study 19 and SOLO2/ENGOT-ov21. We performed multivariable Cox regression analysis based on pre-treatm..View full abstract
This work was supported by AstraZeneca. This work was written by the authors with no medical writing support, input or other involvement by the funder.